SC 13G: Kyverna Therapeutics, Inc.
Ticker: KYTX · Form: SC 13G · Filed: Feb 14, 2024 · CIK: 1994702
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Kyverna Therapeutics, Inc..
Risk Assessment
Risk Level: low
Filing Stats: 1,260 words · 5 min read · ~4 pages · Grade level 10.1 · Accepted 2024-02-14 17:20:59
Key Financial Figures
- $0.00001 — INC. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class
Filing Documents
- d779591dsc13g.htm (SC 13G) — 46KB
- 0001193125-24-036609.txt ( ) — 48KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information in this statement is true, complete and correct. Dated: February 14, 2024 Bain Capital Life Sciences Opportunities III, LP By: Bain Capital Life Sciences Opportunities III GP, LLC, its general partner By: Bain Capital Life Sciences Fund III, L.P., its sole member By: Bain Capital Life Sciences III General Partner, LLC, its general partner By: Bain Capital Life Sciences Investors, LLC, its manager By: /s/ Adam Koppel Name: Adam Koppel Title: Partner